Across TCGA pan-cancer cohorts, ARMCX6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARMCX6 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARMCX6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARMCX6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where ARMCX6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.619	0.955	.002	17	view →
LUAD	OS	Quartile	All	0.892	0.391	.016	16	view →
LSCC	DFS	Median	All	0.201	0.785	.031	8	view →
HNSC	DFS	Median	II,III,IV	1.000	0.363	.021	6	view →
GBM	OS	Median	All	0.358	0.606	.003	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ARMCX6 tumor-vs-normal RNA expression · all ARMCX6 data types